Datavault AI (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This expansion signals a significant move toward decentralized patient data ownership, where individuals can control and monetize their health information. The partnership leverages Datavault AI’s expertise in AI-driven data valuation and Web 3.0 monetization, combined with DataMEDS’ focus on blockchain-based pharmaceutical logistics. By extending into commercial healthcare, the companies aim to address growing demands for data privacy and personalized medicine, potentially disrupting traditional health data management systems.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The company’s technology suite includes the Information Data Exchange, which enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata. For more details, the full press release is available at https://ibn.fm/vBAxH.
The global health and wellness market is projected to grow substantially, and patient-controlled data models could become a cornerstone of future healthcare systems. Datavault AI’s stock performance and investor sentiment may be influenced by this strategic pivot into healthcare, as the company diversifies beyond its core acoustic sciences division. The agreement also highlights the growing intersection of blockchain, AI, and healthcare, where real-world asset tokenization of health data could unlock new value streams.
Datavault AI is headquartered in Philadelphia, PA, and its data science division leverages Web 3.0 and high-performance computing for experiential data perception and secure monetization. The company’s forward-looking statements caution that risks and uncertainties could cause actual results to differ materially, as detailed in its SEC filings. The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.
